Annovis CEO Challenges Alzheimer’s Single-Protein Focus at Fierce Biotech Week
Event summary
- Annovis Bio CEO Maria Maccecchini to present on multi-protein model of Alzheimer’s at Fierce Biotech Week 2026 on May 13.
- Presentation argues against amyloid-centric approach, advocates for targeting multiple neurotoxic proteins.
- Annovis’ lead drug buntanetap in Phase 3 trials, designed to inhibit translation of multiple neurotoxic proteins.
- Event includes Q&A with over 100 biotech CEOs and 500 companies in attendance.
The big picture
Annovis’ presentation challenges the dominant amyloid-centric approach in Alzheimer’s research, aligning with a growing trend toward multi-target therapies in neurodegenerative diseases. The company’s Phase 3 trial for buntanetap could validate this strategy, potentially reshaping the competitive landscape in Alzheimer’s drug development.
What we're watching
- Therapeutic Approach
- Whether Annovis’ multi-protein strategy can gain broader acceptance in the Alzheimer’s research field.
- Clinical Progress
- The pace at which buntanetap advances through Phase 3 trials and potential regulatory approval.
- Market Positioning
- How Annovis differentiates itself from competitors focusing on single-protein targets like amyloid.
Related topics